Lianhuan Pharmaceutical: The supplementary application for the increase of 10ml:1.5g specification of potassium chloride injection by its holding subsidiary has been approved.

Sina Finance News on March 30th, Lianhuan Pharmaceutical announced that its holding subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for Potassium Chloride Injection. The approval allows for the supplement application to increase the 10ml:1.5g specification, issue a drug approval number, and pass the evaluation of generic drug quality and efficacy consistency.